REVISIONS OR AMENDMENTS Sample Clauses

REVISIONS OR AMENDMENTS. No revisions or amendments shall be made to this Program except with the written approval of the parties hereto. This Program shall be effective November 17, 1999, and shall remain in effect for the duration of the Project unless terminated or amended by mutual consent. SUBSTANCE ABUSE PREVENTION AND DETECTION THRESHOLD LEVELS CONTROLLED SUBSTANCE* SCREENING METHOD SCREENING LEVEL** CONFIRMATION METHOD CONFIRMATION LEVEL Amphetamines EMIT 1000 ng/ml** GC/MS 500 ng/ml** Barbiturates EMIT 300 ng/ml GC/MS 200 ng/ml Benzodiazepines EMIT 300 ng/ml GC/MS 300 ng/ml Cocaine EMIT 300 ng/ml** GC/MS 150 ng/ml** Methadone EMIT 300 ng/ml GC/MS 100 ng/ml Methaqualone EMIT 300 ng/ml GC/MS 300 ng/ml Opiates EMIT 2000 ng/ml** GC/MS 2000 ng/ml** PCP (Phencyclidine) EMIT 25 ng/ml** GC/MS 25 ng/ml** THC (Marijuana) EMIT 50 ng/ml** GC/MS 15 ng/ml** Propoxyphene EMIT 300 ng/ml GC/MS 100 ng/ml Alcohol Breathalyzer .04 Percent Breathalyzer .04 Percent * All controlled substances including their metabolite components ** SAMHSA specified threshold A sample reported positive contains the indicated drug at or above the cutoff level for that drug. A negative sample either contains no drug or contains a drug below the cutoff level. Testing levels may be changed to meet SAMSHA or revised industry standards. EMIT – Enzyme immunoassay GC/MS – Gas Chromatography/Mass Spectrometry I am familiar with my obligations under the Link Light Rail and Sounder Commuter Project Substance Abuse Prevention Program. I also understand that the Program specifically requires that:  Use, possession or sale of controlled substances or alcohol at the Project site is prohibited.  Violation of this rule, or conviction for selling, using, or possessing controlled substances on or off the Project, will cause me to be barred from the Project.  Use of prescribed or over-the-counter medication is permitted if it will not affect work performance.  If prescribed or over-the-counter medication could affect work performance I must notify my Contractor-employer prior to using such substances on the job.  I must submit to screening/testing for controlled substances, adulterants and alcohol as requested by the Contractor in accordance with the terms of the Program.  The presence of one or more of a controlled substance, adulterant or alcohol in my system at or above the defined threshold levels will result in termination of employment and ineligibility for reemployment for at least ninety (90) calendar days.  If ter...
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
REVISIONS OR AMENDMENTS. This Substance Abuse Program may be amended, from time-to-time, in writing, signed by Harvard University and any affected Union party to the Agreement.
Sample 1Sample 2Sample 3
REVISIONS OR AMENDMENTS. This Terms and Conditions may be revised or amended at any time. All revisions or amendments shall be posted in the Platform or through email notification to all Members. All changes shall have immediate effect and your continued use of the Platform signifies your continuing acceptance of, understanding and agreement to all the provisions herein and to its future revised versions.
Sample 1Sample 2
REVISIONS OR AMENDMENTS. No revisions or amendments shall be made to this Program except with the written approval of the parties hereto. This Program shall be effective upon the mutual signing of the Agreement, and shall remain in effect for the duration of the projects unless terminated or amended by mutual consent. CONTROLLED SUBSTANCE METHOD SCREENING LEVEL SCREENING Amphetamines EMIT 500 ng/ml** Barbiturates EMIT 300 ng/ml Benzodiazepines EMIT 300 ng/ml Cocaine EMIT 150 ng/ml** Methadone EMIT 300 ng/ml Oxycodone Screen EMIT 100 ng/ml Opiates EMIT 2000 ng/ml** PCP EMIT 25 ng/ml** (Phencyclidine) THC EMIT 50 ng/ml** (Marijuana) Propoxyphene EMIT 300 ng/ml Alcohol Breathalyzer .04 Percent CONFIRMATION METHOD CONFIRMATION LEVEL Amphetamines GC/MS 250 ng/ml** Barbiturates GC/MS 200 ng/ml Benzodiazepines GC/MS 300 ng/ml Cocaine GC/MS 100 ng/ml Methadone GC/MS 100 ng/ml** Oxycodone Screen GC/MS 100 ng/ml Opiates GC/MS 2000 ng/ml** PCP GC/MS 25 ng/ml** (Phencyclidine) THC GC/MS 15 ng/ml** (Marijuana) Propoxyphene GC/MS 100 ng/ml
Sample 1
REVISIONS OR AMENDMENTS. When an accepted document is revised or amended, only that portion affected by the proposed change needs to be evaluated, provided there is no effect on other portions or other documents.
Sample 1

Related to REVISIONS OR AMENDMENTS

  • Other Amendments The parties may amend this Agreement to add, change or eliminate terms for this Agreement if: (i) the holder of the Residual Interest delivers an Officer’s Certificate to the Indenture Trustee and the Owner Trustee stating that the amendment will not have a material adverse effect on the Notes or, if such Officer’s Certificate is not or cannot be delivered, the consent of the Noteholders of a majority of the Note Balance of each Class of the Notes Outstanding (with each Class voting separately, except that all Noteholders of the Class A Notes will vote together as a single class) is received; (ii) the holder of the Residual Interest delivers an Opinion of Counsel to the Indenture Trustee and the Owner Trustee stating that the amendment will not (A) cause a Note to be deemed sold or exchanged for purposes of Section 1001 of the Code, (B) cause the Issuer to be treated as an association or publicly traded partnership taxable as a corporation for U.S. federal income tax purposes or (C) adversely affect the treatment of the Notes as debt for U.S. federal income tax purposes; and (iii) the consent of the Indenture Trustee is received if the amendment has a material adverse effect on the rights or obligations of the Indenture Trustee, which consent will not be unreasonably withheld.

  • General Amendments Without the consent of the Noteholders but after notifying the Rating Agencies, the Issuer and the Indenture Trustee may, and when directed by Issuer Order will, amend this Indenture: (i) to correct or expand the description of property subject to the Lien of this Indenture, or better to assure, convey and confirm to the Indenture Trustee property subject or required to be subjected to the Lien of this Indenture, or to subject additional property to the Lien of this Indenture; (ii) to evidence the succession of any other Person to the Issuer, and the assumption by the successor of the obligations of the Issuer in this Indenture and in the Notes; (iii) to add to the obligations of the Issuer, for the benefit of the Noteholders, or to surrender a right or power given to the Issuer in this Indenture; (iv) to transfer, assign, mortgage or pledge property to or with the Indenture Trustee; (v) to clarify an ambiguity, correct an error or correct or supplement a term in this Indenture inconsistent with another term in this Indenture or to add terms which are not inconsistent with the other terms of this Indenture if the action does not have a material adverse effect on the interests of the Noteholders; (vi) to evidence the acceptance of the appointment under this Indenture of a successor trustee and to add to or change this Indenture necessary for the administration of the trusts under this Indenture by more than one trustee; or (vii) to modify, eliminate or add to the terms of this Indenture to effect the qualification of this Indenture under the TIA and to add to this Indenture other terms required by the TIA.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!